CAROL A. FULCHER, PH.D., AWARDED THE INTERNATIONAL PRIZE OF THE FRENCH ASSOCIATION OF HEMOPHILIA

LA JOLLA, CA Aug. 30, 1990 -- Carol A. Fulcher, Ph.D., of La Jolla, was presented the International Prize of the French Association of Hemophilia during the 19th International Congress of the World Federation of Hemophilia in Washington, D.C., on August 16.

Fulcher is an assistant member in the Department of Molecular and Experimental Medicine and the Committee for the Study of Vascular Biology at Scripps Clinic and Research Foundation.

The prize recognizes those who have made significant contributions to research in hemophilia A pathophysiology, genetics or therapy. Hemophilia A is a genetically determined disease that affects about one in 10,000 male infants, and the average cost of therapy is $10,000 to $60,000 per year.

Fulcher collaborated with the late Theodore S. Zimmerman, M.D., to develop a purification process for blood coagulation Factor VIII (the blood coagulation protein used to treat hemophilia) using monoclonal antibodies. Fulcher was honored for this discovery, which resulted in the production of the first
commercially available, highly purified concentrate of Factor VIII, which allows hemophiliacs to be treated with a greatly reduced risk of AIDS, hepatitis and other viral infections. Fulcher was also honored for her work on the structure and function of the Factor VIII molecule and the immunochemistry of human Factor VIII inhibitor antibodies.

Fulcher is currently researching the biochemistry of Factor VIII, which could lead to improved diagnostic and therapeutic options in both hemophilia A and thrombosis.

###